Identification of novel cannabinoid receptor ligands via evolutionary de novo design and rapid parallel synthesis

QSAR and Combinatorial Science

Volumn 23, Issue 6, 2004, Pages 426-430

  Rogers Evans, Mark ^a   Alanine, Alexander I ^a   Bleicher, Konrad H ^a   Kube, Dagmar ^a   Schneider, Gisbert ^a,b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTORS; COMPOUND COLLECTIONS; CORPORATES; DE NOVO DESIGN; HIT RATE; ORDERS OF MAGNITUDE; PARALLEL SYNTHESIS; RECEPTOR LIGANDS;

CHELATION;

CANNABINOID RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIGAND;

ALGORITHM; ARTICLE; DRUG DESIGN; DRUG SYNTHESIS; PARALLEL DESIGN; PARALLEL SYNTHESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 8544222806     PISSN: 1611020X     EISSN: None     Source Type: Journal    
DOI: 10.1002/qsar.200410012     Document Type: Article

References (34)

1. D. R. Flower, Biochim. Biophys. Acta, 2001, 1422, 207.
2. G. Müller, Curr. Med. Chem. 2000, 7, 861.
3. a) P. H. Reggio, Curr. Med. Chem., 1999, 6(8), 665;
4. b) J. W. Huffman, R. Mabon, M. J. Wu, J. Lu, R. Hart, D. P. Hurst, P. H. Reggio, J. L. Wiley, B. R. Martin, Bioorg. Med. Chem., 2003, 11, 539;
5. c) J. Barnett-Norris, D. P. Hurst, D. L. Lynch, F. Guarnieri, A. Makriyannis, P. H. Reggio, J. Med. Chem., 2002, 45, 3649;
6. d) Z. H. Song, CA. Slowey, D. P. Hurst, PH. Reggio, Mol. Pharmacol., 1999, 56, 834.
7. a) J. Drews, Science, 2000, 287, 1960;
8. b) F. L. Stahura, J. Barorath, Drug Discovery Today 2002, 6, 338.
9. R. D. Ghose, V. N. Viswanadhan, eds. Combinatorial Library Design and Evaluation, Marcel Dekker: New York, Basel, 2001.
10. A. Tropsha, W. Zheng, Comb. Chem. High Throughput Screen. 2002, 5, 111.
11. a) J. S. Mason, I. Morize, P. Menard, D. L. Cheney, C. Hulme, R. F. Labaudiniere, J. Med. Chem. 1999, 42, 3251;
12. b) A. A. Patchett, R. P. Nargund, Ann. Rep. Med. Chem. 2000, 35, 289.
13. a) A. R. Leach, R. A. Bryce, A. J. Robinson, J. Mol. Graph. Model 2000, 18, 358;
14. b) G. Schneider, H.-J. Böhm, Drug Discov. Today 2002, 7, 64.
15. a) G. Schneider, M.-L. Lee, M. Stahl, P. Schneider, J. Comput. Aided Mol. Des. 2000, 14, 487;
16. b) G. Schneider, O. Chomienne-Clement, L. Hilfiger, S. Kirsch, H.-J. Böhm, P. Schneider, W. Neidhart, Angew. Chemie Int. Ed. Engl. 2000, 39, 4130.
17. A. T. Khanolkar, S. L. Palmer, A. Makriyannis, Chem. Phys. Lipids, 2000, 108, 37.
18. a) R. Ciccocioppo, L. Antonelli, M. Biondini, M. Perfumi, P Pompei, M. Massi, Eur. J. Pharmacol. 2002, 449, 245;
19. b) C. S. Freedland, J. S. Poston, L. J. Porrino, Pharmacol. Biochem. Behav. 2000, 67, 265.
20. a) F. Barth, M. Rinaldi-Carmona, Curr. Med. Chem. 1999, 6, 745;
21. b) J. L. Wiley, D. R. Compton, D. Dai, J. A. H. Lainton, M. Phillips, J. W. Huffman, B. R. Martin, J. Pharmacol. Exp. Ther. 1998, 285, 995.
22. J. A. H. Lainton, J. W. Huffman, B. R. Martin, D. R. Compton, Tetrahedron Lett. 1995, 36, 1401.
23. X. Q. Lewell, D. B. Judd, S. P. Watson, M. M. Hann, J. Chem. Inf. Comput. Sci. 1998, 38, 511.
24. G Schneider, S.-S. So, Adaptive Systems in Drug Design, Landes Bioscience: Georgetown, 2001.
25. a) G. Schneider, W. Neidhart, T. Giller, G. Schmid, Angew. Chemie Int. Ed. 1999, 38, 2894;
26. b) G. Schneider, In Virtual Screening for Bioactive Molecules, H.-J Böhm and G. Schneider, Wiley-VCH: Weinheim, 2000, 161.
27. C. W. Andrews, L. Bennett. L. X. Yu, Pharm. Res. 2000, 17, 639.
28. F. Z. Dörwald, In Organic Synthesis on Solid Phase, Wiley-VCH: Weinheim, 2000, 290.
29. N. Plobeck, D. Delorme, Z.-Y. Wei, H. Yang, F. Zhou, P. Schwarz, L. Gawell, H. Gagnon, B. Pelcman, R. Schmidt, S. Y. Yue, C. Walpole, W. Brown, E. Zhou, E. Labarre, K. Payza, S. St-Onge, A. Kamassah, P. -E. Morin, D. Projean, J. Ducharme, E. Roberts, J. Med. Chem. 2000, 43, 3878.
30. 3H)-CP55,940 (1.5 nM final), 2.5 μl test compound diluted in DMSO (0-10 μM final (10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003 μM), and 7.5 μg of membrane protein. Nonspecific binding was determined in the presence of 1 mM cold CP55.940. Reactions were incubated for one hour at 30 degrees, filtered onto GF/B plates (pretreated with 0.3% polyethylenimine) using a Packard Micromate 196, and washed ten times with cold wash buffer (50 mM Tris and 0.5% fatty acid-free BSA). Plates were dried for one hour at 50°C and counted on a topcounter after adding Microscint 0 to each well.
31. P. R. Eastwood, Tetrahedron Lett. 2000, 41, 3705.
32. Affinities for the NK-1 receptor were evaluated in CHO cells infected with the human NK-1 receptor and radiolabled with [3H] Substance P. Affinities for the D2 receptor were evaluated in CHO cells transfected with the human D2 receptor and radiolabled with [3H] Spiperone. Affinities for the mGlu5 receptor were evaluated in HEK-293 cells transfected with the human mGlu5 receptor and radiolabled with [3H] MPEP. Affinities for the A2a receptor were evaluated in CHO cells transfected with the human A2a receptor and radiolabled with [3H] SCH58261.
33. A. Alanine, K. Bleicher, W. Guba, W. Haap, D. Kube, T. Luebbers, J. -M. Plancher. M. Rogers-Evans, G. Schneider, J. Zuegge, O. Roche, PCT Int. Appl. 2004, WO 2004013120.
34. T. Langer, R. D. Hoffmann, Curr. Pharm. Des. 2001, 7, 509.